URGN FY 2021 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$48M+307.2% YoY

Gross Profit

$43M89.3% margin

Operating Income

-$92M-192.1% margin

Net Income

-$111M-230.7% margin

EPS (Diluted)

$-4.96

Cash Flow

Operating Cash Flow

-$85M

Free Cash Flow

-$86M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$120M

Total Liabilities

$111M

Stockholders' Equity

$8M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$12M	+307.2%
Gross Profit	$43M	$11M	+297.5%
Operating Income	-$92M	-$127M	+27.2%
Net Income	-$111M	-$128M	+13.7%